María José Carmena Sierra-rekin lankidetzan egindako argitalpenak (8)

2005

  1. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K

    Prostate, Vol. 63, Núm. 1, pp. 44-55

2004

  1. Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells

    Regulatory Peptides, Vol. 119, Núm. 1-2, pp. 69-75

2003

  1. VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal

    British Journal of Pharmacology, Vol. 139, Núm. 5, pp. 1050-1058

2001

  1. Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors

    Cellular Signalling, Vol. 13, Núm. 12, pp. 887-894

1997

  1. Ontogenic development of the adenylyl cyclase enzyme and the α(s), α(i1) and α(i2) G-protein regulatory subunits from rat prostate

    Cellular Signalling, Vol. 9, Núm. 6, pp. 451-456

1996

  1. Modulation of cyclic AMP and inositol phosphate production in rat prostatic cultures by VIP/PACAP, ATP, and carbachol: Role in prostatic proliferation

    Annals of the New York Academy of Sciences

  2. Modulation of cyclic AMP and inositol phosphate production in rat prostatic cultures by VIP/PACAP, ATP, and carbachol: Role in prostatic proliferation

    VIP, PACAP, AND RELATED PEPTIDES, 2ND INTERNATIONAL SYMPOSIUM

1994

  1. Ontogeny of vasoactive intestinal peptide receptors in rat ventral prostate

    General Pharmacology, Vol. 25, Núm. 3, pp. 509-514